Diabetes and Hypertension
Diabetes and Hypertension
Part of NephTimes Diseases and Conditions
Advertisement
Victoria SochaDiabetes and Hypertension | February 5, 2024
Patients with diabetic kidney disease face increased risk of end-stage kidney disease and dialysis.
Read More
Victoria SochaDiabetes and Hypertension | February 5, 2024
Albuminuria, hypertension, declining kidney function, and an increase in cardiovascular risk are all hallmarks of DKD.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Strategies for the accurate evaluation of the risk of fragility fractures in elderly patients in the early stages of DKD.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Compared with DPP4 inhibitors, SGLT2 inhibitors were associated with a lower risk for the kidney-specific outcome.
Victoria SochaDiabetes and Hypertension | February 5, 2024
In patients with type 2 diabetes mellitus, identifying nondiabetic kidney disease is crucial in delaying progression of CKD.
Victoria SochaChronic Kidney Disease | February 5, 2024
Development and validation of a model to predict future trajectories in eGFR in adults with type 2 diabetes and CKD.
Victoria SochaChronic Kidney Disease | February 5, 2024
A 2004 landmark study demonstrated an association between chronic kidney disease and an increased risk of CV events.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Early diagnosis of CKD and active management can slow progression and improve outcomes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Using antihypertensive medication in patients with persistent treatment-resistant hypertension concurrent with CKD.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Albuminuria is a strong determinant of kidney and cardiovascular risk in those with and without type 2 diabetes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Patients with type 2 diabetes without other comorbidity are often treated with metformin as antiglycemic therapy.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Previous studies have documented associations between chronic kidney disease (CDK), obesity, and metabolic syndrome.
Victoria SochaDiabetes and Hypertension | February 5, 2024
There was no association between systolic IABPD and eGFR in the multiple linear regression model.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Examining the occurrence of proteinuria and impairment in renal function in a cohort of living hypertensive kidney donors.
Victoria SochaHyperkalemia | February 5, 2024
At the 12-month follow-up, 100% of patients in the patiromer group remained on RAAS inhibitor therapy.
Victoria SochaHyperkalemia | February 5, 2024
Concerns related to hyperkalemia are key in patients with CKD who are receiving other hyperkalemia-inducing agents.
Victoria SochaDiabetes and Hypertension | February 5, 2024
In those with more nephrology visits in the proceeding 12 months, the odds of SGLT2 inhibitor prescription were lower.
Victoria SochaDiabetes and Hypertension | February 5, 2024
The prevalence of CKD and cost of screening were the most influential parameters.
Victoria SochaDiabetes and Hypertension | February 5, 2024
A report on outcomes of kidney transplant recipients treated with SGLT2 inhibitors.
Victoria SochaDiabetes and Hypertension | February 5, 2024
The predictive power of ESRD progression was high with choline, myo-inositol, and citrate.
Advertisement
Advertisement
Advertisement
Latest News

March 1, 2024